Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Fate Therapeutics, Inc. NASDAQ:FATE | $271.58M | $2.33 | Not rated | -1.8 | +0.00% |
Alector, Inc. NASDAQ:ALEC | $262.02M | $2.36 | Not rated | -1.4 | +110.66% |
PepGen Inc. NASDAQ:PEPG | $217.19M | $3.14 | Not rated | -1.6 | -30.74% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $192.32M | $10.38 | Not rated | -1.3 | -76.78% |
Nkarta, Inc. NASDAQ:NKTX | $190.31M | $2.66 | Not rated | -2.0 | -35.75% |
Molecular Partners AG NASDAQ:MOLN | $165.05M | $4.40 | Not rated | -2.0 | -36.40% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $67.83M | $0.88 | Not rated | -1.8 | -58.05% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $57.96M | $3.04 | Not rated | -1.7 | -66.67% |
Actuate Therapeutics Inc NASDAQ:ACTU | $30.39M | $1.27 | Not rated | -2.3 | -64.27% |
Continue the stock analysis
Jump to another research area for this company.